The seventh edition of the non-small cell lung cancer (NSCLC) TNM staging system was
developed by the International Association for the Staging of Lung Cancer (IASLC) Lung …

Checkpoint blockades turn on a new paradigm shift in immunotherapy for cancer.
Remarkable clinical efficacy, durable response and low toxicity of programmed death 1 (PD …

Programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) pathway
blockade is a promising new cancer therapy. Although PD-1/PD-L1 treatment has yielded …

Background We assessed the efficacy and safety of programmed cell death 1 (PD-1)
inhibition with pembrolizumab in patients with advanced non–small-cell lung cancer …

Circulating soluble programmed death-1 ligand (sPD-L1) is measurable in the serum of
cancer patients. This study aimed to investigate the significance of sPD-L1 in cancer patients …

With the understanding of the complex interaction between the tumour microenvironment
and immunotherapy, there is increasing interest in the role of immune regulators in the …

Background The potential predictive role of programmed death-ligand-1 (PD-L1) expression
on tumor cells in the context of solid tumor treated with checkpoint inhibitors targeting the PD …

Tumors can evade immune detection by exploiting inhibitory immune checkpoints such as
the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway …

Introduction Immune escape frequently occurs and restricts the durability of the antitumor
immune response to radiotherapy. Programmed death 1 (PD-1) and programmed death …

Although many studies have addressed the prognostic value of programmed cell death-
ligand 1 (PD-L1) expression in lung cancer, the results remain controversial. A systematic …